We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug giants turn their backs on RNA interference.
- Authors
Ledford, Heidi
- Abstract
The article focuses on the trends in RNA interference (RNAi) research in 2010. It states that Roche Pharmaceuticals has announced that it will shut its RNAi research programme on November 17, 2010 after three years of operation, which shows the potential lose in momentum of RNAi platform in pharmaceutical industry. It says that Novartis AG ended its partnership with Alnylam Pharmaceuticals Inc., but Alnylam will continue develop RNAi-based drugs generated during its partnership with Novartis .
- Subjects
ROCHE Pharmaceuticals Ltd.; PHARMACEUTICAL industry; NOVARTIS AG; BUSINESS partnerships; ALNYLAM Pharmaceuticals Inc.; DRUG development
- Publication
Nature, 2010, Vol 468, Issue 7323, p487
- ISSN
0028-0836
- Publication type
Article
- DOI
10.1038/468487a